molecules of the month


orally active beta-1,3-glucan synthesis inhibitor

eff. in fungal infect. model, discont. for alt.

from semisynthetic mod. of enfumafungin

Bioorg. Med. Chem. Lett., Jun. 19, 2020

Merck & Co., Kenilworth, NJ / Scynexis

1 min read

MK-5204 is a broad spectrum Candida antifungal agent derived from the natural product, enfumafungin. I was impressed that the molecule not only demonstrates oral efficacy but also has good oral PK in higher species (dog, cyno), given that the molecule is a large zwitterion with several very polar groups, including a primary amide, primary amine, carboxylic acid, and triazole. Development of this molecule was discontinued in favor of a further optimized analog, ibrexafungerp (MK-3118, SCY-078), currently in phase III clinical trials.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: